Company Overview and News

 
Half-year Report

2017-03-02 londonstockexchange
The Directors of Mosman Oil and Gas Limited (AIM: MSMN) the New Zealand ("NZ") and Australia focussed oil exploration and development company, today released the Company's Condensed Consolidated Half Year Financial Report for the 6 months ended 31 December 2016.

 
I-Minerals Strenghtens Board of Directors With Addition of John Theobald

2016-07-21 marketwired
VANCOUVER, BC--(Marketwired - July 21, 2016) - I-Minerals Inc. (TSX VENTURE: IMA) (OTCQB: IMAHF) ("I-Minerals") is pleased to announce that it has appointed John Theobald to its Board of Directors. Mr. Theobald, a resident of London, England, brings capital markets, senior management expertise and industrial minerals marketing experience to I-Minerals and is expected to be a regular contributor to the day to day operations of the company and its longer term success.

 
Appendix 3B - Escrow Release

2016-05-06 asx.com.au

 
Release of Shares from Escrow

2016-05-06 asx.com.au

 
March Quarterly Activities Report

2016-04-29 asx.com.au

 
March Quarterly Cashflow Report

2016-04-29 asx.com.au

 
Half Yearly Report

2016-03-29 londonstockexchange
Mosman Oil and Gas Limited (AIM: MSMN) the New Zealand and Australia focussed oil exploration and development company, announces its Half Yearly Results for the six months to 31 December 2015, which are contained in the Condensed Consolidated Half Year Financial Report for the period.

 
Change in substantial holding

2016-03-07 asx.com.au

 
Mosman Oil and Gas cancels sale and purchase agreement for acquisition of South Taranaki Energy Project

2016-02-01 oilvoice
Mosman Oil and Gas Limited (AIM: MSMN) the New Zealand and Australia focussed oil exploration and development company, announces an update on the prop...

 
 
 
Change in substantial holding

2015-12-23 asx.com.au

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

2018-05-21 - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

2018-05-21 - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...